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Abstract: Objective: platelets possess not only haemostatic but also inflammatory properties, which
combined are thought to play a detrimental role in thromboinflammatory diseases such as acute
coronary syndromes and stroke. Phosphodiesterase (PDE) 3 and -5 inhibitors have demonstrated
efficacy in secondary prevention of arterial thrombosis, partially mediated by their antiplatelet action.
Yet it is unclear whether such inhibitors also affect platelets’ inflammatory functions. Here, we
aimed to examine the effect of the PDE3A inhibitor cilostazol and the PDE5 inhibitor tadalafil on
platelet function in various aspects of thromboinflammation. Approach and results: cilostazol, but
not tadalafil, delayed ex vivo platelet-dependent fibrin formation under whole blood flow over
type I collagen at 1000 s−1. Similar results were obtained with blood from Pde3a deficient mice,
indicating that cilostazol effects are mediated via PDE3A. Interestingly, cilostazol specifically reduced
the release of phosphatidylserine-positive extracellular vesicles (EVs) from human platelets while
not affecting total EV release. Both cilostazol and tadalafil reduced the interaction of human platelets
with inflamed endothelium under arterial flow and the release of the chemokines CCL5 and CXCL4
from platelets. Moreover, cilostazol, but not tadalafil, reduced monocyte recruitment and platelet-
monocyte interaction in vitro. Conclusions: this study demonstrated yet unrecognised roles for
platelet PDE3A and platelet PDE5 in platelet procoagulant and proinflammatory responses.
Keywords: platelets; thrombosis; vascular inflammation; phosphodiesterase inhibitors; extracellu-
lar vesicles
1. Introduction
In atherosclerosis and its major clinical presentation, myocardial infarction and stroke,
there is a strong crosstalk between inflammatory and thrombotic processes. For instance,
platelets are considered to promote atherogenesis by recruiting leukocytes to the inflamed
endothelium (via chemokines) and by triggering an inflammatory response in endothelial
cells through direct interaction or with released extracellular vesicles (EVs) [1]. Prevention
of recurrent cardiovascular events predominantly comprises therapy with platelet activa-
tion inhibitors, such as aspirin and clopidogrel, or dual pathway inhibition with a low
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dose anticoagulant on top of aspirin [2]. Despite this comprehensive treatment, a quarter
of the yearly arising strokes and myocardial infarcts are reoccurring [3,4], highlighting
a need for new or additional treatment options.
In contrast to standard antiplatelet and anticoagulant drugs, which dampen platelet or
coagulant activity, phosphodiesterase (PDE) inhibitors act by promoting vasodilation and
platelet inhibitory pathways [5]. The PDEs 2, 3, and 5 are expressed in platelets and hydrol-
yse cAMP (PDE2, PDE3) and cGMP (PDE2, PDE3, PDE5) to adenosine monophosphate
and guanosine monophosphate, respectively, thereby lowering the threshold for platelet
activation [5]. Whereas PDE2 inhibitors are still under preclinical development, the PDE3A
inhibitor cilostazol (IC50 PDE3 inhibition: 0.2 µM) is prescribed to alleviate symptoms
of intermittent claudication in patients with peripheral artery disease and for secondary
stroke prevention [6–8]. Notably, cilostazol, as opposed to aspirin and clopidogrel, does
not influence bleeding time [9,10]. The PDE5 inhibitor dipyridamole was formerly used
as a standard treatment for secondary stroke treatment in combination with aspirin, but
current guidelines now advise monotherapy with aspirin or with clopidogrel [11–14].
Dipyridamole (IC50 PDE5 inhibition: 0.9 µM) is known for its antithrombotic action. How-
ever, the platelet inhibiting function of dipyridamole does not only rely on its action via
PDE5, but also on the blockage of adenosine reuptake [15]. In contrast to dipyridamole,
tadalafil (IC50 PDE5 inhibition: 1.8 nM), sildenafil (IC50 PDE5 inhibition: 5.22 nM), and
vardenafil (IC50 PDE5 inhibition: 0.7 nM) have a high specificity in only inhibiting PDE5,
and these compounds are used for the treatment of erectile dysfunction [5]. Tadalafil
and sildenafil are also beneficial in pulmonary arterial hypertension [16]. The effect of
PDE3 inhibition on haemostatic or thrombotic platelet activation and aggregation has been
explored widely, but research on cilostazol in platelet proinflammatory function is limited.
Moreover, research about PDE5 inhibition with its specific inhibitor tadalafil with regard to
a thrombotic or inflammatory state is scarce.
Here, we examine the effect of the PDE3A inhibitor cilostazol and the PDE5 inhibitor
tadalafil on platelet function in various aspects of thromboinflammation.
2. Methods
2.1. Blood Collection
Human blood was obtained from healthy donors after full informed consent in com-
pliance with the Declaration of Helsinki. Studies were approved by the local Medical
Ethics Committee. Users of antiplatelet and/or anticoagulant medication were excluded.
Regarding the flow experiments under inflammatory conditions, human whole blood
was kindly provided by the Experimental Centre for Technical Medicine at the University
of Twente.
2.2. Mice
Animal experiments were approved by the Ethics Committee for Animal Well-Being
of the Faculty of Medicine, Université Libre de Bruxelles (ULB), protocol LA1230331-621N,
in line with the regional and national regulations and the EU directives. Mice were bred
and maintained under standard husbandry conditions and a regular diet in the animal
facility of the Faculty of Medicine, ULB. Genotyping was performed as described [17]. Male
and female C57BL/6 wild type (WT) and Pde3a deficient (knockout; KO) mice between
10 and 26 weeks old were anaesthetized by intraperitoneal injection with 800 µL avertin,
which was the standard procedure approved by the Ethical Committee for the procurement
of biological materials for ex vivo studies. The effects of the anaesthesia were verified
by checking the foot reflex. No postanaesthetic effects were present as the mice were
directly euthanized by cervical dislocation after blood collection on 3.2% sodium citrate via
retro-orbital puncture.
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2.3. Cell Culture
Human umbilical vein endothelial cells (HUVECs) were cultured in ECGM medium
(PromoCell) in a humidified atmosphere with 5% CO2 at 37 ◦C. HUVECs between passage
5 and 7 were used.
Human acute monocytic leukaemia (THP-1) cells were cultured in RPMI-1640 Gluta-
MAX medium supplemented with 20% FCS and 1% penicillin/streptomycin in a humidi-
fied atmosphere with 5% CO2 at 37 ◦C. THP-1 cells between passage 5 and 16 were used.
2.4. Statistical Analysis
Flow perfusion experiments over collagen were analysed with a two-way ANOVA,
except for the time to fibrin formation with the pharmacological intervention, which
was tested with an ordinary one-way ANOVA. Paired t-tests were performed for flow
perfusion experiments over inflamed endothelium. The experiments regarding THP-1
migration, cAMP/cGMP levels and VASP phosphorylation were analysed with a Kruskal–
Wallis test. THP-1 adhesion was evaluated with a Wilcoxon matched-pairs signed rank
test. Statistical testing for the remaining experiments was performed using an ordinary
one-way ANOVA. Correction for multiple comparisons was achieved with Dunnett’s,
Dunn’s, Sidak’s and Holm-Sidak’s post hoc testing. All data were statistically analysed
with Graphpad Prism 8.4.3.
3. Results
3.1. Function of PDE3A and PDE5 in P-Selectin Expression and αIIbβ3 Activation of Human and
Mouse Platelets
To determine the effects of cilostazol and tadalafil on platelet activation markers,
washed human platelets were incubated with increasing concentrations of these com-
pounds prior to stimulation with the collagen-analogue CRP (0.3 µg/mL) and analysed by
flow cytometry (Figure 1A). In suspension, cilostazol dose dependently inhibited platelet
integrin αIIbβ3 activation and the secretion of platelet α- and dense granules (Figure 1B).
Tadalafil significantly inhibited platelet integrin activation at 5 nM and above, while secre-
tion of α-granules was only decreased at 20 and 50 nM. Dense granule secretion was not
affected at these concentrations (Figure 1C). In resting or CRP-stimulated washed platelets,
incubation with cilostazol or with tadalafil neither led to significantly altered cAMP and
cGMP levels nor to altered phosphorylation of VASP at serine-157 or -239 (Supplementary
Table S1 and Supplementary Figure S2).
Surprisingly, in platelets from WT or Pde3a KO mice measured with flow cytometry,
integrin αIIbβ3 activation and α-granule secretion were unaltered upon stimulation of
diluted whole blood with increasing doses of the platelet agonists ADP, AYPGKF (PAR4)
or CRP (GPVI) (Supplementary Figure S3). There were no indications of platelet pre-
activation as activation markers of unstimulated platelets levels were <3% (Supplementary
Figure S3).
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Figure 1. PDE3A and PDE5 inhibition dose-dependently decreases platelet integrin activation and granule secretion. 
Washed platelets were activated with collagen-related peptide (CRP, 0.3 μg/mL) and platelet integrin αIIbβ3 activation 
(PAC-1: 65.68 ± 17.42%) and platelet α-granule secretion (CD62P: 72.74 ± 8.17%), dense-granule secretion (CD63: 20.36 ± 
13.97%) were measured by flow cytometry (A). Dose-dependent decrease by PDE3A (B) and PDE5 (C) inhibition. Data in 
duplicate in the percentage normalised against the activated platelets without inhibitor are shown. Corresponding vehicle 
controls were included for every condition. Histograms: black represents control, red represents CRP, pink represents 
cilostazol (5 μM), and blue represents tadalafil (10 nM). Mean + S.D., n = 5–7, * p < 0.05, *** p < 0.001, **** p < 0.0001. Statistics: 
ordinary one-way ANOVA followed by Holm-Sidak’s multiple comparisons test. CRP, collagen-related peptide. 
Surprisingly, in platelets from WT or Pde3a KO mice measured with flow cytometry, 
integrin αIIbβ3 activation and α-granule secretion were unaltered upon stimulation of di-
luted whole blood with increasing doses of the platelet agonists ADP, AYPGKF (PAR4) 
or CRP (GPVI) (Supplementary Figure S3). There were no indications of platelet pre-acti-
vation as activation markers of unstimulated platelets levels were <3% (Supplementary 
Figure S3). 
3.2. PDE3A, but Not PDE5, Inhibition Delays Platelet-Dependent Coagulation, while 
Maintaining Initial Haemostatic Thrombus Formation in Human and Mouse Platelets 
Haemostatic platelet thrombus formation involves reciprocal interaction between 
platelets and coagulation factors [18]. To our knowledge, we are the first to assess the role 
of PDE3A and PDE5 on in vitro platelet thrombus formation under coagulating conditions 
using pharmacological inhibitors and blood from mice deficient in Pde3a. Notably, global 
Pde5a KO mice are embryonically lethal and no conditional Pde5a KO mouse models exist 
[19]. 
Upon perfusion, human platelets adhered instantaneously to the collagen I and tissue 
factor surface and formed large and fibrin-rich thrombi with an average time to fibrin 
formation of 302 s. Platelet-collagen interaction as such was not affected by cilostazol (50 
Figure 1. PDE3A and PDE5 inhibition dose-dependently decreases platelet integrin activation and granule secretion. Washed
platelets were activated with collagen-related peptide (CRP, 0.3 µg/mL) and platelet integrin αIIbβ3 activation (PAC-1:
65.68 ± 17.42%) and platelet α-granule secretion (CD62P: 72.74 ± 8.17%), dense-granule secretion (CD63: 20.36 ± 13.97%)
were measured by flow cytometry (A). Dose-dependent decrease by PDE3A (B) and PDE5 (C) inhibition. Data n duplicate
in the perce tage normalis d against the activated platelets without inhibit r are shown. Corresponding vehicle controls
were included for every condition. Histograms: black represents control, red represents CRP, pink represents cilostazol
(5 µM), and blue represents tadalafil (10 nM). Mean + S.D., n = 5–7, * p < 0.05, *** p < 0.001, **** p < 0.0001. Statistics:
ordinary one-way ANOVA followed by Holm-Sidak’s multiple comparisons test. CRP, collagen-related peptide.
3.2. PDE3A, but not PDE5, Inhibition Delays Platelet-Dependent Coagulation, while Maintaining
Initial Haemostatic Thrombus Formation in Human and Mouse Platelets
Haemostatic platelet thrombus formation involves reciprocal interaction between
platelets and coagulation factors [18]. To our knowledge, we are the first to assess the role
of PDE3A and PDE5 on in vitro platelet thrombus formation under coagulating conditions
using pharmacological inhibitors and blood from mice deficient in Pde3a. Notably, global
Pde5a KO mice are embryonically lethal and no conditional Pde5a KO mouse models
exist [19].
Upon perfusion, human platelets adhered instantaneously to the collagen I and tissue
factor surface and formed large and fibrin-rich thrombi with an average time to fibrin
formation of 302 s. Platelet-collagen interaction as such was not affected by cilostazol
(50 µM, 95–98% protein-bound in plasma) or tadalafil (100 nM, 94% protein-bound in
plasma) as the integrated feature size, which reflects platelet surface area coverage with
respect to large thro bi and smaller platelet clusters [20], was unaltered (Figure 2A,B).
Interestingly, cilostazol, but not tadalafil, significantly increased time to fibrin formation
to 384 s (p = 0.03, Figure 2C). The surface area coverage of the platelet activation markers
fibrin(ogen), CD62P and CD63 was unaltered (Supple entary Figure S4).
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Figure 2. Effects of PDE inhibition or genetic deletion on platelet-dependent coagulation under flow over collagen. Recal-
cified citrate-anticoagulated human (A–C) or mouse (D–G) blood was perfused over a collagen type I surface or a com-
bined collagen type I plus tissue factor surface for 7 (mouse) or 8 (human) min at a wall shear rate of 1000 s−1. (A) Repre-
sentative brightfield images after 8 min of blood perfusion without inhibitor (0.1% ethanol) or in the presence of cilostazol 
(50 μM) or tadalafil (100 nM). Quantitative analysis of integrated feature size (μm) (B) and time to fibrin formation (C). 
Representative brightfield images of blood perfusion of WT mice and Pde3a KO mice over collagen type I without (D) or 
with (E) tissue factor in the absence of iloprost under coagulating conditions. Quantitative analysis of integrated feature 
size (F) and time to fibrin (G). Scale is 20 μm. Mean ± S.D., n = 4–6 (human) or 4–5 (mouse), * p < 0.05. Statistics: two-way 
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Figure 2. Effects of PDE inhibition or genetic deletion on platelet-dependent coagulation under flow over collagen.
Recalcified citrate-anticoagulated human (A–C) or mouse (D–G) blood was perfused over a collagen type I surface or
a combined collagen type I plus tissue factor surface for 7 (mouse) or 8 (human) min at a wall shear rate of 1000 s−1.
(A) Representative brightfield images after 8 min of blood perfusion without inhibitor (0.1% ethanol) or in the presence
of cilostazol (50 µM) or tadalafil (100 nM). Quantitative analysis of integrated feature size (µm) (B) and time to fibrin
formation (C). Representative brightfield images of blood perfusion of WT mice and Pde3a KO mice over collagen type
I without (D) or with (E) tissue factor in the absence f iloprost under coagulati g conditions. Quanti ative analysis of
ntegrate feature s ze (F) and time to fibrin (G). Scale is 20 µm. Mean ± S.D., n = 4–6 (human) or 4–5 (mouse), * p < 0.05.
Statistics: two-way ANOVA followed by Dunnett’s (B) or Sidak’s (F,G) multiple comparisons test. Ti e to fibrin formation
(human) was tested by ordinary one-way ANOVA followed by Holm-Sidak’s multiple comparisons test (C). Ilo, iloprost;
KO, knockout; TF, tissue factor; WT, wild type.
In a similar experimental setup, thrombus formation with blood from Pde3a KO mice
was compared to that of WT mice (Figure 2D–F). Mouse thrombi were analysed based
on their morphologic appearance, in which the integrated feature size was significantly
decreased with blood Pde3a KO mice upon perfusion over the collagen type I surface, in
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the absence of tissue factor (p = 0.05, Figure 2F). When coagulation was stimulated by
including the tissue factor in the collagen type I surface, the differences between WT and
KO mice were abolished (Figure 2F). No phenotypic differences of thrombi were observed
between genotypes (Supplementary Figure S5). To expand the experimental window for
picking up an effect of PDE3 inhibition in mice, iloprost was added to the blood, which
caused a raise in cAMP levels. In our hands, such an experimental window is smaller in
mouse platelets when compared to human platelets as mouse platelets are more easily
activated with, as a consequence, lower basal cAMP levels. Interestingly, the time to fibrin
formation was increased in blood from Pde3a KO mice in comparison to blood from WT
mice, in the presence of iloprost (Figure 2G). When investigating the activation markers of
adherent platelets, the surface area coverage of JON/A, CD62P, or annexin V was found
to be uniform among WT and Pde3a KO mice (Supplementary Figure S4). Altogether,
these data suggest a promoting role for PDE3A, but not PDE5, in platelet-dependent fibrin
formation, with platelet-collagen interaction under flow ranging from mildly inhibited to
unaltered depending on the extent of coagulation.
3.3. PDE3A and PDE5 Inhibition Decreases Platelet Adhesion to Inflamed Endothelial Cells
Next, we investigated the role of PDE3A under thromboinflammatory conditions, first
specifically in platelet-endothelial interactions, in which different receptors are involved
than in platelet interactions with vascular matrix components [21,22]. Healthy endothelial
cells ensure platelet quiescence, among others via the secretion of prostacyclin and nitric
oxide [23], and indeed, hardly any platelet adhesion was visible during and after whole
blood perfusion over untreated endothelial cells (Supplementary Figure S6). Inflamma-
tory conditions were created by overnight or 4 h stimulation of HUVECs with TNF-α
(10 ng/mL), which gave similar results (Supplementary Figure S6). Whole blood perfusion
over inflamed endothelial cells resulted in the adhesion of single platelets, which clustered
but remained a single layer of platelets (Figure 3A). Pre-treatment of blood from healthy
volunteers with cilostazol reduced platelet adhesion on the inflamed endothelium, already
at a dosage which is 10-fold lower (5 µM, Figure 3B) than was used for the platelet-collagen
interaction experiments (Figure 2). Interestingly, incubation with 10 nM tadalafil, which
is a 10-fold lower dose than the one used for platelet-collagen interaction under flow
(Figure 2), inhibited platelet-endothelial interaction to a similar extent as cilostazol. These
data suggest that pharmacological inhibition of PDE3A and PDE5 inhibits interactions of
platelets with inflamed endothelium.




Figure 3. Platelet adhesion on inflamed endothelium is decreased upon PDE3A or -5 inhibition. Recalcified citrate-antico-
agulated human blood was perfused over HUVECs treated with 10 ng/mL TNF-α for 10 min at a wall shear rate of 1000 
s−1. (A) Representative brightfield images after 10 min of blood perfusion without inhibitor (0.1% ethanol) or in the pres-
ence of cilostazol (5 μM) or tadalafil (10 nM). (B) Quantitative analysis of platelet surface area coverage. Scale is 100 μm. 
Interquartile range, n = 4–6, * p < 0.05. Statistics: paired t-test. 
3.4. Monocyte Migration to and Adhesion on Platelets Is Reduced by Inhibition of PDE3A but 
Not of PDE5 
In the context of (thrombo)inflammation, platelets facilitate monocyte activation and 
migration into the endothelium via chemotaxis and via direct interaction with monocytes 
[1,24]. Platelet-induced monocyte migration was studied with a chemotaxis chamber (Fig-
ure 4). Washed platelets already induced migration of THP-1 cells without the addition of 
a platelet agonist (Figure 4A,B), which is suggestive of platelet activation in the well. Plate-
let activation with CRP showed a positive trend (p = 0.11) to further increased THP-1 cell 
migration. Cilostazol (5 μM) pre-treatment diminished the CRP-induced chemotaxis, 
whereas PDE5 inhibition with tadalafil showed no effect (Figure 4B). Subsequently, we 
studied the effect of PDE3A inhibition on monocyte adhesion to a platelet monolayer, 
formed on a collagen type I surface, under flow conditions. Inhibition of PDE3A caused a 
relatively small, but significant (p = 0.04), reduction in THP-1 adhesion to platelets (Figure 
4C,D). Taken together, inhibition of PDE3A and thus increasing cAMP in platelets de-
creased both platelet-induced monocyte migration as well as the adhesion of monocytes 
on platelets. 
Figure 3. Platelet adhesion on inflamed endothelium is decreased upon PDE3A or -5 inhibition. Recalcified citrate-
anticoagulated human blood was perfused over HUVECs treated with 10 ng/mL TNF-α for 10 min at a wall shear rate
of 1000 s−1. (A) Representative brightfield images after 10 min of blood perfusion without inhibitor (0.1% ethanol) or in
the presence of cilostazol (5 µM) or tadalafil (10 nM). (B) Quantitative analysis of platelet surface area coverage. Scale is
100 µm. Interquartile range, n = 4–6, * p < 0.05. Statistics: paired t-test.
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3.4. Monocyte Migration to and Adhesion on Platelets Is Reduced by Inhibition of PDE3A but not
of PDE5
In the context of (thrombo)inflammation, platelets facilitate monocyte activation and
migration into the endothelium via chemotaxis and via direct interaction with mono-
cytes [1,24]. Platelet-induced monocyte migration was studied with a chemotaxis chamber
(Figure 4). Washed platelets already induced migration of THP-1 cells without the addition
of a platelet agonist (Figure 4A,B), which is suggestive of platelet activation in the well.
Platelet activation with CRP showed a positive trend (p = 0.11) to further increased THP-1
cell migration. Cilostazol (5 µM) pre-treatment diminished the CRP-induced chemotaxis,
whereas PDE5 inhibition with tadalafil showed no effect (Figure 4B). Subsequently, we stud-
ied the effect of PDE3A inhibition on monocyte adhesion to a platelet monolayer, formed
on a collagen type I surface, under flow conditions. Inhibition of PDE3A caused a relatively
small, but significant (p = 0.04), reduction in THP-1 adhesion to platelets (Figure 4C,D).
Taken together, inhibition of PDE3A and thus increasing cAMP in platelets decreased both
platelet-induced monocyte migration as well as the adhesion of monocytes on platelets.




Figure 4. PDE3A inhibition decreases platelet-induced migration and platelet-induced adhesion of 
THP-1 cells under flow. Representative images (A) and quantitative analysis (B) of THP-1 cell mi-
gration to medium and to washed platelets, untreated or additionally stimulated with CRP and 
inhibited with cilostazol (5 μM) or tadalafil (10 nM). Red arrows indicate THP-1 cells. Representa-
tive images (C) or quantitative analysis (D) of THP-1 adhesion to collagen alone, and to washed 
platelets in the absence or presence of cilostazol (5 μM). Interquartile range (B), mean ± S.D. (D), n 
= 6 (A,B) or 7 (C,D), * p < 0.05. Statistics: Kruskal–Wallis test followed by Dunn’s multiple compari-
sons test (B) and Wilcoxon matched-pairs signed rank test (D). Cilo, cilostazol; CRP, collagen-re-
lated peptide; plt, platelets; tada, tadalafil. 
3.5. Platelet Chemokine- and Procoagulant EV Release Are Regulated by PDE3A and Partly by 
PDE5 
Platelet chemokines promote leukocyte recruitment to the inflamed endothelium 
[1,24]. We examined the effect of PDE3A and PDE5 inhibition on the release of the chem-
okines CCL5 (RANTES) and CXCL4 (platelet factor 4) by platelets. Convulxin- or throm-
bin-activated platelets secreted a substantial amount of CCL5 and CXCL4 (Figure 5A,B, p 
< 0.0001, Supplementary Figure S7). Both cilostazol and tadalafil reduced this chemokine 
release (Figure 5A,B, p < 0.01, Supplementary Figure S7), implicating a thus far unexplored 
role for PDE3A and -5 signalling in the secretion of proinflammatory factors from plate-
lets. 
Platelet-derived EVs play an important role in both haemostasis and inflammation 
and other cardiovascular diseases [25,26]. NTA was used to measure total platelet EV re-
lease. Stimulation of platelets with convulxin or thrombin resulted in a 3.3-fold and 2.4-
fold increase in EV release, respectively (Supplementary Figure S7C,D, p < 0.01). Neither 
cilostazol (5 μM) nor tadalafil (10 nM) affected the total platelet EV release induced by 
convulxin (Figure 5C) or thrombin (Supplementary Figure S7). Cells can shed various EV 
subtypes, among which procoagulant EVs have gained considerable attention [27]. Pro-
coagulant (PS-positive) platelet EV release, determined with a prothrombinase-based as-
say and expressed as the amount of lipids (nM), was increased after platelet stimulation 
with convulxin (12.2-fold, Figure 5D, p < 0.01, Supplementary Figure S7D) or with throm-
bin (5.9-fold, Supplementary Figure S7, p < 0.001). PDE5 inhibition was not associated with 
altered procoagulant EV release. Importantly, cilostazol significantly decreased procoag-
ulant EV release induced by convulxin (Figure 5D, p = 0.02), whereas it showed a tendency 
of reduction in procoagulant EVs after platelet stimulation with thrombin (Supplementary 
Figure S7, p = 0.08). 
Fig re 4. PDE3A inhibition decreases platelet-induced migration and platelet-induced adhesi n
of THP-1 cells under flow. R presentat ve images (A) and quantitative analysis (B) of THP-1 cell
migration to medium and to washed plat lets, untreated or a ditionally stimulated with
inhibited ith cilostazol (5 µ ) or tadalafil (10 nM). Red arrows indicate THP-1 cells. Representative
images (C) or quantitative analysis (D) of THP-1 adhesion to collagen alone, and to washed platelets
in the absence or presence of cilostazol (5 µM). Interquartile range (B), mean ± S.D. (D), n = 6 (A,B) or
7 (C,D), * p < 0.05. Statistics: Kruskal–Wallis test followed by Dunn’s multiple comparisons test
(B) and Wilcoxon matched-pairs signed rank test (D). Cilo, cilostazol; CRP, collagen-related peptide;
plt, platelets; tada, tadalafil.
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CVX; NTA), 9–11 (cilo, tada; NTA), 21–22 (control, CVX; PTase), 4–5 (cilo, tada; PTase), * p < 0.05, ** 
p < 0.01, *** p < 0.001, **** p < 0.0001. Statistics: ordinary one-way ANOVA followed by Dunnett’s 
(A,B) or Holm-Sidak’s (C,D) multiple comparisons test. Cilo, cilostazol; CVX, convulxin; NTA, na-
noparticle tracking analysis; PTase, prothrombinase; tada, tadalafil. 
4. Discussion 
Platelets are increasingly considered to not only have a main role in haemostasis and 
thrombosis, but also to be important in other conditions, such as vascular inflammation 
[28,29]. In so-called thromboinflammatory diseases, mechanisms of thrombosis and in-
flammation are intertwined, and can elicit and amplify one another. Here we report yet 
unrecognised roles for PDE3A and PDE5 in platelet procoagulant and proinflammatory 
responses. We found that PDE3A, but not PDE5, promotes platelet-dependent coagula-
tion, through the delay of platelet-dependent fibrin formation and the reduction in pro-
coagulant platelet EV release. With respect to proinflammatory responses, we observed 
that PDE3A and PDE5 promote platelet chemokine release and the interaction of platelets 
with inflamed endothelium. Platelet PDE3A also promotes monocyte recruitment and 
platelet-monocyte interaction. 
Pharmacological inhibition of both PDE3A and -5 led to an unaltered platelet surface 
area coverage, platelet integrin activation, and granule secretion on collagen type I under 
flow. This might seem in contrast to previous studies that found reduced thrombus vol-
ume and platelet aggregation under shear flow [30–36]. However, these studies were per-
formed in the absence of coagulation. The experimental setting in our study encompassed 
coagulating conditions, which is an important difference in methodology, since thrombus 
formation and coagulation are interconnected by the interaction of platelets with coagu-
lation factors [18]. For example, thrombin generated on the platelet thrombi, being a po-
tent agonist, might dampen the effects of cilostazol on integrin activation, secretion, and 
thrombus formation. Notably, cilostazol did reduce integrin activation and secretion of α- 
and dense granules of washed platelets under noncoagulating conditions, which is in 
agreement with others [37–39]. 
Figure 5. Effect of P E3 and -5 inhibition on convulxin-induced chemokine and extracellular vesicle
release by platelets. Washed platelets were stimulated with convulxin (100 ng/mL) withou or with
cilostaz l (5 µM) or tadalafil (10 nM), and the release of chemokines CCL5 (A) and CXCL4 (B), and of
total (C) and procoagulant (D) platelet extracellular vesicle (EV) was measured. (A,B) Mean ± S.D.,
n = 27–29 (control, CVX) or 10–11 (cilo, tada). (C,D) Interquartile range, n = 15–16 (control, CVX;
NTA), 9–11 (cilo, tada; NTA), 21–22 (control, CVX; PTase), 4–5 (cilo, tada; PTase), * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001. Statistics: ordinary one-way ANOVA followed by Dunnett’s (A,B) or
Holm-Sidak’s (C,D) multiple comparisons test. Cilo, cilostazol; CVX, convulxin; NTA, nanoparticle
tracking analysis; PTase, prothrombinase; tada, tadalafil.
Platelet-derived EVs play an important role in both haemostasis and inflammation
and other cardiovascular diseases [25,26]. NTA was used to measure total platelet EV
release. Stimulation of platelets with convulxin or thrombin resulted in a 3.3-fold and
2.4-fold increase in EV release, respectively (Supplementary Figure S7C,D, p < 0.01). Nei-
ther cilostazol (5 µM) nor tadalafil (10 nM) affected the total platelet EV release induced
by convulxin (Figure 5C) or thrombin (Supplementary Figure S7). Cells can shed vari us
EV subtypes, among which procoagulant EVs have gained considerable attention [27].
Procoagulant (PS-positive) platelet EV release, determined with a prothrombinase-based
assay d expressed as the amount of li ids (nM), was increased after platelet stimulation
with convulxi (12.2-fold, Figure 5D, p < 0.01, Supplem ntary Figure S7D) or with thrombin
(5.9-fold, Suppl mentary Figure S7, p < 0.001). PDE5 inhibition was no associa ed with al-
tered proc agulant EV release. Importantly, cilostazol significantly decreased procoagulant
EV rele se induced by convulxin (Figure 5D, p = 0.02), whereas it showed t ndency of
reduction in procoagulant EVs after platelet stimulation wi h thrombin (Suppl me tary
Figure S7, p = 0.08).
Taken tog ther, the above findings suggest that the pathways of proinflammato y
platelet functions are regul ted throug the actions of PDE3A a d PDE5, although pot n-
tially in different ways.
4. Discussion
Platelets are increasi gly considered to not only have a main role in haemostasis
and thrombosis, but also to be important in other conditions, such as vascular inflamma-
tion [28,29]. In so-called thromboinflammatory diseases, mechanisms of thrombosis and
infla mation are intertwined, and can elicit and amplify one another. Here we report yet
unrecognised roles for PDE3A and PDE5 in platelet procoagulant and proinflammatory
responses. We found that PDE3A, but not PDE5, promotes platelet-dependent coagulation,
through the delay of platelet-dependent fibrin formation and the reduction in procoag-
ulant platelet EV release. With respect to proinflammatory responses, we observed that
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PDE3A and PDE5 promote platelet chemokine release and the interaction of platelets
with inflamed endothelium. Platelet PDE3A also promotes monocyte recruitment and
platelet-monocyte interaction.
Pharmacological inhibition of both PDE3A and -5 led to an unaltered platelet surface
area coverage, platelet integrin activation, and granule secretion on collagen type I un-
der flow. This might seem in contrast to previous studies that found reduced thrombus
volume and platelet aggregation under shear flow [30–36]. However, these studies were
performed in the absence of coagulation. The experimental setting in our study encom-
passed coagulating conditions, which is an important difference in methodology, since
thrombus formation and coagulation are interconnected by the interaction of platelets with
coagulation factors [18]. For example, thrombin generated on the platelet thrombi, being
a potent agonist, might dampen the effects of cilostazol on integrin activation, secretion,
and thrombus formation. Notably, cilostazol did reduce integrin activation and secretion
of α- and dense granules of washed platelets under noncoagulating conditions, which is in
agreement with others [37–39].
Our pharmacological studies were complemented by ex vivo perfusion using whole
blood from Pde3a KO mice. Pde3a KO platelets displayed normal integrin activation and
thrombus formation, but an increased time to fibrin formation under coagulating conditions.
These results correspond to the pharmacological PDE3A inhibition using cilostazol in
human platelets and suggest that this delay in fibrin formation can be attributed to direct
actions on PDE3A enzyme activity and not by e.g., blockage of adenosine reuptake, as
observed with dipyridamole. Yet, in contrast to treatment of human platelets with cilostazol,
we found integrin αIIbβ3 activation and CD62P expression in flow cytometry to be unaltered
in Pde3a KO platelets after stimulation with various platelet agonists. This might reflect
experimental differences in responses of the washed human platelets compared to those
in diluted mouse whole blood. Alternatively, the findings raise the question on the role
of PDE3A in activation of mouse platelets versus human platelets. One explanation for
our results might be different amounts of the enzymes in platelets; human platelets have
on average 1400 copies of PDE3A and 10,900 copies PDE5 per platelet [40], and mouse
platelets contain 3400 copies of PDE3A and 50,382 of PDE5 [41]. Evidence on the role of
PDE3A in murine platelet activation is scarce in the literature. One study reported that
cAMP concentrations in resting Pde3a KO platelets was twice as high as in WT counterparts,
which would suggest that these Pde3a KO platelets have a higher activation threshold [42].
Previous studies have largely focused on the role of cilostazol on the (non-inflamed)
endothelium with respect to platelet-endothelium interaction, but such data are lacking
for tadalafil. Cilostazol was found to directly act on the endothelium by inducing NO
production [43], and by suppressing expression of endothelial P-selectin and intercellular
adhesion molecule-1 (ICAM-1) [44], which will dampen platelet activation and platelet-
endothelial interaction [21]. Our findings demonstrate that cilostazol and tadalafil reduce
the adhesion of platelets in whole blood to activated endothelial cells under arterial shear
conditions. As endothelial cells also contain PDE3A and PDE5 and both inhibitors are
present during the perfusion experiments, a role for endothelial PDE3/PDE5 in the reduced
platelet-endothelium interaction with cilostazol and tadalafil cannot be excluded a priori.
However, this would involve an instantaneous alteration of expressed receptors for platelet
adhesion in activated endothelial cells, which is rather unlikely. Our findings with cilostazol
extend those by Fukuoka et al. [45], who found that cilostazol inhibits platelet-endothelial
cell interaction in murine cerebral microvessels after transient bilateral common carotid
artery occlusion using infusion of labelled platelets obtained from a donor mouse. Of note,
it is unclear from the article whether these donor platelets were also treated with cilostazol
or not. In addition, elevation of cAMP in platelets by cilostazol was shown to reduce
initial platelet accumulation at sites of laser-induced endothelial injury in vivo [46]. Taken
together, our data suggest that platelet PDE3A and PDE5 do not only regulate thrombotic
platelet responses, but also platelet function under inflammatory conditions.
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During previous years, the importance of platelets in vascular inflammation and
inflammatory diseases has been recognised, in which not only platelet-endothelial in-
teractions are involved, but also the interplay between platelets and leukocytes [47,48].
Migration and adhesion of monocytes towards and onto platelets was decreased upon
PDE3A inhibition, although the inhibiting effects observed for monocyte adhesion were
not as pronounced as for monocyte migration. Our findings extend earlier work in which
a similar reduction by cilostazol treatment in binding of monocytes to collagen-activated
platelets was observed, albeit under static conditions in a flow cytometer [37]. In order
to investigate the effects of PDE inhibition on the release of inflammatory mediators, we
focused on the chemokines CCL5 and CXCL4, which are abundantly expressed in human
platelets. In addition, the release of these chemokines correlates strongly with that of other
α-granule associated proteins after activation [49]. Importantly, we show that platelet
PDE3A inhibition resulted in a strong reduction of the release of chemokines CCL5 and
CXCL4, which is in agreement with the reduction in α-granule release by PDE3 inhibi-
tion. These chemokines promote the adhesion of monocytes to endothelial cells [50,51].
Interestingly, PDE5 inhibition decreased the release of CCL5 and CXCL4, while leaving
monocyte migration unaffected. Beyond monocyte recruitment, CCL5 and in particular
CXCL4 are also involved in neutrophil recruitment and activation, T cell differentiation,
and injury responses of vascular smooth muscle cells [52–55]. Thus, the inhibition of CCL5
and CXCL4 release from platelets might be beneficial for the prevention of these patho-
logical effects. In summary, cilostazol inhibits monocyte recruitment to, and adhesion on,
platelets, presumably via the reduced release of CCL5 and CXCL4. This might also extend
to other chemokines released from platelets with relevance for vascular inflammation and
remodelling, e.g., CXCL14 and CXCL12 [56,57]. For future studies, it would be of interest
to implement modern OMICs to investigate whether PDE inhibition leads to changes in
platelet lipid composition [58] or RNA contents [59].
In our study, neither cilostazol nor tadalafil altered total platelet EV levels measured
by nanoparticle tracking analysis. Conflicting reports exist about the effect of cilostazol
on platelet EV release [60]. No role of PDE3A inhibition in platelet EV release was found
when this was measured with an ELISA [61,62]. In contrast, cilostazol decreased total
platelet EV levels determined with flow cytometry [36,39,63–66]. The lack of consistent
effects of cilostazol on EV release is presumably related to the method of characterization,
emphasising the need for standardisation [26].
Platelet extracellular vesicles exert procoagulant properties [67,68]. The increased pro-
coagulant activity in stroke and myocardial infarct patients is characterised by phosphatidyl-
serine- (PS) or tissue factor expressing cells and extracellular vesicles [69–72]. We are
the first to distinguish between total EV levels and the number of procoagulant EVs in
the context of phosphodiesterase inhibition. We found reduced procoagulant (PS-positive)
extracellular vesicle release by cilostazol but not by tadalafil. Interestingly, acetylsalicylic
acid had no effect on either total EV release in stroke patients nor proinflammatory or
procoagulant EV release [72]. A remaining question is how and to what extent our proco-
agulant EV fraction differs from our total EV fraction and therefore, an important next step
would be to fully characterise the platelet extracellular vesicles using fluorescent markers to
obtain an advanced perspective of distinct EV subtypes, in healthy subjects and in various
platelet-associated diseases.
Taken together, our findings demonstrate that the PDE3A inhibitor cilostazol not only
delays platelet-dependent fibrin formation and platelet procoagulant EV release, but also
dampens platelet-mediated inflammatory responses. It would be of particular interest to
examine whether cilostazol treatment also affects platelet (procoagulant) EVs in patients
and whether the EV level is associated with (reduced) thrombotic events.
5. Highlights
• We identified novel roles for platelet PDE3A and PDE5 in promoting procoagulant
and proinflammatory platelet functions.
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• PDE3A inhibition with cilostazol reduced procoagulant extracellular vesicle release.
• Release of the chemokines CCL5 and CXCL4 was decreased by either cilostazol or
the PDE5 inhibitor tadalafil.
• Our findings add mechanistic insight substantiating a beneficial effect of cilostazol in
thromboinflammatory diseases.
Supplementary Materials: Extensive methods and Supplementary Figures are outlined in the article
supplement at https://www.mdpi.com/article/10.3390/cells10081998/s1. Figure S1: Flow cytome-
try gating strategy; Figure S2: Effects of PDE inhibition on VASP phosphorylation; Figure S3: Platelets
from Pde3a KO mice show normal αIIbβ3 integrin activation and α-granule secretion; Figure S4:
Effects of PDE inhibition or genetic deletion on platelet activation markers under flow over collagen
under coagulating conditions; Figure S5: Pde3a KO mice show normal platelet thrombus formation
depending on morphology, contraction, and multilayer; Figure S6: Influence of the duration of TNF-α
treatment of endothelial cells on platelet surface area coverage. Figure S7: Influence of PDE3A and -5
inhibition on thrombin-induced chemokine and extracellular vesicle release by platelets. Table S1:
Effects of PDE inhibition on platelet cAMP and cGMP levels.
Author Contributions: D.M.C. contributed to the study conceptualisation, methodology, formal
analysis, investigation, visualisation and writing—original draft preparation. A.C.A.H. and M.J.E.K.
contributed to investigation and formal analysis. H.J.A., S.O. and P.H. contributed to methodology,
resources and investigation. M.N. contributed to methodology, investigation, formal analysis, and
writing—review and editing. J.-M.V. contributed to resources and writing—review and editing. M.P.
and A.D.v.d.M. contributed to methodology and resources. R.R.K. contributed to the study concep-
tualisation, methodology, visualisation and writing—review and editing. J.M.E.M.C. contributed
by funding acquisition, project administration, supervision, study conceptualisation, methodol-
ogy, resources, visualisation, writing—review and editing. All authors have read and agreed to
the published version of the manuscript.
Funding: This work was funded by the Dutch Heart Foundation [2015T79 to D.M.C and J.M.E.M.C.];
the Netherlands Organisation for Scientific Research [NWO Vidi 91716421 to J.M.E.M.C.]; the Euro-
pean Research Council [ERC Advanced ‘VESCEL’ to H.J.A.]; and the European Union [Horizon 2020
Marie Sklodowska-Curie ‘EVOluTION’ No. 675111 to S.O. and M.P.].
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki, and approved by the Medical Ethics Committee of Maastricht University
(protocol 2017-0285) and the Experimental Centre for Technical Medicine of the University of Twente.
Animal experiments were approved by the Ethics Committee for Animal Well-Being of the Faculty of
Medicine, Université Libre de Bruxelles (ULB), protocol LA1230331-621N, in line with the regional
and national regulations and the EU directives.
Informed Consent Statement: Informed consent was obtained from all subjected involved in
this study.
Data Availability Statement: Data are available upon reasonable request from the corresponding
author. Reagents and detailed methods of all procedures are provided in the Data Supplement.
Acknowledgments: We wish to acknowledge Joel Moss and Steven Hockman from the NIH/NHLBI,
who kindly granted us the permission to use the Pde3a knockout mice, originating from the lab of
Vincent Manganiello (deceased).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Coenen, D.M.; Heinzmann, A.C.A.; Karel, M.F.A.; Cosemans, J.M.E.M.; Koenen, R.R. The multifaceted contribution of platelets in
the emergence and aftermath of acute cardiovascular events. Atherosclerosis 2021, 319, 132–141. [CrossRef] [PubMed]
2. Weitz, J.I.; Angiolillo, D.J.; Geisler, T.; Heitmeier, S. Dual pathway inhibition for vascular protection in patients with atherosclerotic
disease: Rationale and review of the evidence. Thromb. Haemost. 2020, 120, 1147–1158. [CrossRef] [PubMed]
3. Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; Cushman, M.; Delling, F.N.;
Deo, R.; et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation 2018,
137, e67–e92. [CrossRef]
Cells 2021, 10, 1998 12 of 14
4. World Health Organization. Cardiovascular Diseases (cvds). Available online: https://www.Who.Int/en/news-room/fact-
sheets/detail/cardiovascular-diseases-(cvds) (accessed on 19 February 2019).
5. Gresele, P.; Momi, S.; Falcinelli, E. Anti-platelet therapy: Phosphodiesterase inhibitors. Br. J. Clin. Pharmacol. 2011, 72, 634–646.
[CrossRef]
6. Gerhard-Herman, M.D.; Gornik, H.L.; Barrett, C.; Barshes, N.R.; Corriere, M.A.; Drachman, D.E.; Fleisher, L.A.; Fowkes, F.G.R.;
Hamburg, N.M.; Kinlay, S.; et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral
artery disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice
guidelines. J. Am. Coll. Cardiol. 2017, 69, e71–e126. [CrossRef]
7. Noma, K.; Higashi, Y. Cilostazol for treatment of cerebral infarction. Expert Opin. Pharm. 2018, 19, 1719–1726. [CrossRef]
8. Toyoda, K.; Uchiyama, S.; Yamaguchi, T.; Easton, J.D.; Kimura, K.; Hoshino, H.; Sakai, N.; Okada, Y.; Tanaka, K.; Origasa, H.;
et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan:
A multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019, 18, 539–548. [CrossRef]
9. Tamai, Y.; Takami, H.; Nakahata, R.; Ono, F.; Munakata, A. Comparison of the effects of acetylsalicylic acid, ticlopidine and
cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999, 29, 269–276. [CrossRef]
10. Wilhite, D.B.; Comerota, A.J.; Schmieder, F.A.; Throm, R.C.; Gaughan, J.P.; Rao, A.K. Managing PAD with multiple platelet
inhibitors: The effect of combination therapy on bleeding time. J. Vasc. Surg. 2003, 38, 710–713. [CrossRef]
11. Florescu, C.; Mustafa, E.R.; Târtea, E.A.; Florescu, D.R.; Albu, V.C. Antiplatelet therapy in secondary ischemic stroke
prevention—a short review. Rom. J. Morphol. Embryol. 2019, 60, 383–387.
12. Erdman, M.K.; Leary, M.C. Antiplatelet agents: Mechanisms and their role in stroke prevention. In Primer on Cerebrovascular
Diseases; Academic Press: Cambridge, MA, USA, 2017; pp. 874–881.
13. Bath, P.M.; Woodhouse, L.J.; Appleton, J.P.; Beridze, M.; Christensen, H.; Dineen, R.A.; Duley, L.; England, T.J.; Flaherty, K.;
Havard, D.; et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and
dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial. Lancet
2018, 391, 850–859. [CrossRef]
14. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.;
Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the early management of patients with acute ischemic stroke: 2019
update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from
the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418.
15. Gresele, P.; Zoja, C.; Deckmyn, H.; Arnout, J.; Vermylen, J.; Verstraete, M. Dipyridamole inhibits platelet aggregation in whole
blood. Thromb. Haemost. 1983, 50, 852–856. [CrossRef] [PubMed]
16. Parikh, V.; Bhardwaj, A.; Nair, A. Pharmacotherapy for pulmonary arterial hypertension. J. Thorac. Dis. 2019, 11, S1767–S1781.
[CrossRef] [PubMed]
17. Masciarelli, S.; Horner, K.; Liu, C.; Park, S.H.; Hinckley, M.; Hockman, S.; Nedachi, T.; Jin, C.; Conti, M.; Manganiello, V. Cyclic
nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J. Clin. Investig. 2004, 114, 196–205. [CrossRef]
18. Swieringa, F.; Spronk, H.M.H.; Heemskerk, J.W.M.; van der Meijden, P.E.J. Integrating platelet and coagulation activation in
fibrin clot formation. Res. Pract. Thromb. Haemost. 2018, 2, 450–460. [CrossRef] [PubMed]
19. Zhang, M.; Takimoto, E.; Hsu, S.; Lee, D.I.; Nagayama, T.; Danner, T.; Koitabashi, N.; Barth, A.S.; Bedja, D.; Gabrielson, K.L.; et al.
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J. Am. Coll. Cardiol. 2010,
56, 2021–2030. [CrossRef] [PubMed]
20. de Witt, S.M.; Swieringa, F.; Cavill, R.; Lamers, M.M.E.; van Kruchten, R.; Mastenbroek, T.; Baaten, C.; Coort, S.; Pugh, N.;
Schulz, A.; et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat. Commun.
2014, 5, 4257. [CrossRef]
21. Coenen, D.M.; Mastenbroek, T.G.; Cosemans, J.M.E.M. Platelet interaction with activated endothelium: Mechanistic insights from
microfluidics. Blood 2017, 130, 2819–2828. [CrossRef]
22. Versteeg, H.H.; Heemskerk, J.W.; Levi, M.; Reitsma, P.H. New fundamentals in hemostasis. Physiol. Rev. 2013, 93, 327–358.
[CrossRef]
23. Smolenski, A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J. Thromb. Haemost. 2012, 10, 167–176. [CrossRef]
[PubMed]
24. Rayes, J.; Bourne, J.H.; Brill, A.; Watson, S.P. The dual role of platelet-innate immune cell interactions in thrombo-inflammation.
Res. Pract. Thromb. Haemost. 2020, 4, 23–35. [CrossRef]
25. Vajen, T.; Mause, S.F.; Koenen, R.R. Microvesicles from platelets: Novel drivers of vascular inflammation. Thromb. Haemost. 2015,
114, 228–236. [CrossRef]
26. Dickhout, A.; Koenen, R.R. Extracellular vesicles as biomarkers in cardiovascular disease; chances and risks. Front. Cardiovasc.
Med. 2018, 5, 113. [CrossRef] [PubMed]
27. Gasecka, A.; Nieuwland, R.; Budnik, M.; Dignat-George, F.; Eyileten, C.; Harrison, P.; Huczek, Z.; Kapłon-Cieślicka, A.; Lacroix, R.;
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